- Home
- SLRX vs CANF Comparison
SLRX vs CANF Comparison
Compare SLRX & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLRX | CANF |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | Israel |
| Employees | N/A | 5 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 4.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SLRX | CANF |
|---|---|---|
| Price | $0.79 | $0.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 664.7K | ★ 19.7M |
| Earning Date | 11-14-2025 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $560,000.00 |
| Revenue This Year | N/A | $461.72 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.71 | $0.28 |
| 52 Week High | $108.00 | $2.33 |
Technical Indicators
Market Signals| Indicator | SLRX | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 26.49 | 28.64 |
| Support Level | $0.81 | $0.31 |
| Resistance Level | $0.89 | $0.33 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | 0.10 | -0.00 |
| Stochastic Oscillator | 8.25 | 0.82 |
Price Performance
Historical ComparisonAbout SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).